Patents Examined by J. S. Parkin
-
Patent number: 7220420Abstract: The present invention is directed to a molecule comprising a polypeptide having substantial homology with a CTL epitope selected from the group consisting of ADLMGYIPLV (Core131-140; SEQ ID NO:1), LLALLSCLTV (Core178-187; SEQ ID NO:2), QLRRHIDLLV (SEQ ID NO:55), LLCPAGHAV (NS31169-1177; SEQ ID NO:26), KLVALGINAV (NS31406-1415; SEQ ID NO:28), SLMAFTAAV (NS41789-1797; SEQ ID NO:34), LLFNILGGWV (NS41807-1816; SEQ ID NO:35), and ILDSFDPLV (NS52252-2260; SEQ ID NO:42). Such molecules are used for the treatment and prevention of acute or chronic HCV hepatitis; suitable pharmaceutical compositions and methods using such compositions are disclosed.Type: GrantFiled: May 12, 1997Date of Patent: May 22, 2007Assignee: The Scripps Research InstituteInventors: Francis V. Chisari, Andreas Cerny
-
Patent number: 7189402Abstract: The present invention discloses development of a model live vaccine for HIV, using an attenuated strain of Salmonella engineered to surface express specific HIV proteins and testing of this vaccine in mice. There are provided two recombinant plasmids, containing the Lpp-OmpA genes required for surface exposure, followed by the genes for the HIV-1 proteins, Reverse Transcriptase or Transactivating protein (Tat). These plasmids are electroporated into an attenuated strain of Salmonella, and antigen expression is verified. These live vaccines are then used to orally inoculate mice and the vaccinated mice are tested for fecal IgA response and helper T cell response specific for the HIV antigens.Type: GrantFiled: February 4, 1999Date of Patent: March 13, 2007Assignee: Research Development FoundationInventors: George Barrie Kitto, Mary Susan Burnett
-
Patent number: 7150984Abstract: The present invention provides vaccine compositions of attenuated human rotavirus. More particularly, the attenuated human rotavirus is produced by cold passage and thus contains attenuating mutations which produce virus having a cold-adapted (ca) and temperature sensitive (ts) phenotype. The attenuated strains are used in methods for stimulating the immune system of an individual to induce protection against human rotavirus by administration of the ca attenuated rotavirus.Type: GrantFiled: July 11, 1995Date of Patent: December 19, 2006Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Yasutaka Hoshino, Albert Z. Kapikian, Robert M. Chanock
-
Patent number: 7147862Abstract: The present invention provides vaccine compositions comprising 3 De-O-acylated monophosphoryl lipid A and QS21. The vaccines compositions are potent inducers of CTL and ? IFN responses.Type: GrantFiled: August 12, 1997Date of Patent: December 12, 2006Assignee: SmithKline Beecham Biologicals (S.A.)Inventors: Jean-Paul Prieels, Nathalie Marie-Josephe Claude Garcon-Johnson, Moncef Slaoui, Pietro Pala
-
Patent number: 7122193Abstract: The present invention relates to retro peptides, as well as antibodies thereto, and to their uses, chiefly in the field of preparation of pharmaceutical compositions, in particular vaccines, and for in vitro diagnosis of various pathologies.Type: GrantFiled: April 13, 2000Date of Patent: October 17, 2006Assignee: Biomerieux S.A.Inventors: Gilles Guichard, Slyviane Muller, Jean-Paul Briand, Marc Regenmortel
-
Patent number: 7115363Abstract: The invention relates to a new class of retroviruses, designated by HIV-2, of which samples have been deposited to the ECACC under numbers 87.01.1001 and 87.01.1002 and to the NCIB under numbers 12.398 and 12.399. It relates also to antigens capable to be obtained from this virus, particularly proteins p12, p16, p26 and gp140. These various antigens can be used for the diagnosis of the disease, especially by contacting these antigens with a serum of a patient submitted to the diagnosis. It relates to immunogenic compositions containing more particularly the glycoprotein gp140. Finally it concerns nucleotidic sequences, which can be used especially as hybridization probes, derived from the RNA of HIV-2.Type: GrantFiled: June 6, 1995Date of Patent: October 3, 2006Assignee: Institut PasteurInventors: Luc Montagnier, Solange Chamaret, Denise Guetard, Marc Alizon, François Clavel, Mireille Guyader, Pierre Sonigo, Francoise Brun-Vezinet, Marianne Rey, Christine Rouzioux, Christine Katlama
-
Patent number: 7105655Abstract: The present application is directed to stabilized envelope glycoprotein trimers. The trimers are stabilized by introducing disulfide bonds at certain sites in the gp41 ectodomain. DNA molecules encoding such trimers can be used to generate an immunogenic reaction.Type: GrantFiled: June 25, 2002Date of Patent: September 12, 2006Assignee: Dana-Farber Cancer InstituteInventors: Joseph G. Sodroski, Michael Farzan
-
Patent number: 7105164Abstract: A method of generating an HIV-specific cytotoxic T-cell response in a host involves an initial administration of a T-helper molecule to the host to prime T-helper cells of the immune system of the host and a subsequent administration to the host of a mixture of the T-helper molecule and a T-cell inducing HIV-derived molecule to generate an HIV-specific T-cell response in the host.Type: GrantFiled: April 7, 1999Date of Patent: September 12, 2006Assignee: Sanofi Pasteur LimitedInventors: Charles D. Y. Sia, Pele Chong, Michel H. Klein
-
Patent number: 7087375Abstract: The present invention is directed to the field of HIV resistance to RT inhibitors and methods of determining the levels and mechanisms of action of HIV resistance. The methods of the present invention may be accomplished using a novel in vitro assay that provides a reaction well comprising a template for an HIV RT enzyme, a primer, a detectable dNTP substrate, an HIV RT inhibitor, and a ribonucleotide chosen from ATP and GTP or a pyrophosphate. The RT activity is determined by measuring the amount of the detectable dNTP substrate that is incorporated into the template, and the level and/or mechanism of resistance of HIV to the HIV RT inhibitor is determined using the RT activity. The methods may also be used for designing new therapies, screening for new drugs and treatments, and determining the role of mutations in observed resistance.Type: GrantFiled: June 23, 2000Date of Patent: August 8, 2006Inventors: Johan Lennerstrand, Brendan Larder
-
Patent number: 7083795Abstract: An immunogenic composition capable of producing a respiratory syncytial (RS) virus specific immune response in a host immunized therewith comprises purified, inactivated RS virus which is substantially free from cellular and serum components and which is non-infectious, non-immunopotentiating, immunogenic and protective. The virus is grown on a vaccine quality cell line and harvested virus is purified under non-denaturing conditions to be substantially free from cellular and serum components. The purified RS virus is inactivated using ?-propiolactone, a non-ionic detergent, particularly n-octyl-?-D-glucopyranoside and n-octyl-?-D-glucopyranoside, or ascorbic acid. The immunogenic composition may be formulated as a vaccine for in vivo administration to a human host. The immunogenic composition also may be used in diagnostic applications.Type: GrantFiled: August 4, 1994Date of Patent: August 1, 2006Assignee: Sanofi Pasteur LimitedInventors: Sonia E. Sanhueza, Mary E. Ewasyshyn, Michel H. Klein
-
Patent number: 7081243Abstract: Replication-competent recombinant rhabdoviruses that lack a functional glycoprotein gene and express at least one foreign polypeptide such as a celluar receptor for another virus in their viral envelopes are useful in the treatment of pathogenic viruses. In one embodiment, a recombinant vesicular stomatitis virus (VSV) lacking its glycoprotein (G) gene and expressing instead the HIV receptor and a coreceptor is employed in a method for treating persons infected with HIV. The recombinant virus is defective for entry into normal cells but is able to control HIV infection in a T cell line by replicating in, and killing, HIV-infected cells.Type: GrantFiled: July 10, 1998Date of Patent: July 25, 2006Assignee: Yale UniversityInventors: John K. Rose, Matthias Schnell, E. Erik Johnson
-
Patent number: 7060273Abstract: This invention provides a method of reducing an HIV infected subject's HIV-1 viral load which comprises administering to the subject an effective viral load reducing amount of an antibody which (a) binds to a CCR5 chemokine receptor and (b) inhibits fusion of HIV-1 to a CD4+CCR5+cell, so as to thereby reduce the subject's HIV-1 viral load to 50% or less of the subject's HIV-1 viral load prior to administering the antibody to the subject.Type: GrantFiled: April 5, 2002Date of Patent: June 13, 2006Assignee: Progenics Pharmaceuticals, Inc.Inventors: William C. Olson, Paul J. Maddon
-
Patent number: 7060869Abstract: Fluorescent indicators including a binding protein moiety, a donor fluorescent protein moiety, and an acceptor fluorescent protein moiety are described. The binding protein moiety has an analyte-binding region which binds an analyte and causes the indicator to change conformation upon exposure to the analyte. The donor moiety and the acceptor moiety change position relative to each other when the analyte binds to the analyte-binding region. The donor moiety and the acceptor moiety exhibit fluorescence resonance energy transfer when the donor moiety is excited and the distance between the donor moiety and the acceptor moiety is small. The indicators can be used to measure analyte concentrations in samples, such as calcium ion concentrations in cells.Type: GrantFiled: April 20, 2000Date of Patent: June 13, 2006Assignee: The Regents of the University of CaliforniaInventors: Roger Y. Tsien, Atsushi Miyawaki
-
Patent number: 7056656Abstract: This invention relates to the use of oligourea molecules to specifically inhibit protein-nucleic acid interactions. In particular, it provides an oligourea molecule that competes with the Tat molecule for the TAR RNA of HIV-1. Also provided is a method specifically inhibiting protein-nucleic and interactions, and kits.Type: GrantFiled: January 25, 2000Date of Patent: June 6, 2006Assignee: University of Medicine and Dentistry of New JerseyInventors: Tariq M. Rana, Natarajan Tamilarasu, Ikramul Huq
-
Patent number: 7056658Abstract: Multiple epitope fusion proteins and immunoassays using the same are disclosed. The multiple epitope fusion proteins are encompassed by the general structural formula (A)x?(B)y?C2 which represents a linear amino acid sequence, wherein B is an amino acid sequence of an epitope or cluster of epitopes and each B contains at least five and not more than 1,000 amino acids, y is an integer of 2 or more, A and C are each independently an amino acid sequence of an epitope or cluster of epitopes not adjacent to B in nature and x and z are each independently an integer of 0 or more wherein at least one of x and z is 1 or more.Type: GrantFiled: June 17, 2002Date of Patent: June 6, 2006Assignee: Chiron CorporationInventors: Pablo D. T. Valenzuela, David Ying Chien
-
Patent number: 7041667Abstract: Compounds of Formula 1 [Region ?]—[Region ?]—[Region ?]—[Region ?]??(1) which are useful as modulators of chemokine activity. The invention also provides pharmaceutical formulations and methods of treatment using these compounds.Type: GrantFiled: December 1, 1999Date of Patent: May 9, 2006Assignee: Pfizer, Inc.Inventors: Duncan Robert Armour, David Anthony Price, Blanda Luzia Christa Stammen, Anthony Wood, Manoussos Perros, Martin Paul Edwards
-
Patent number: 7037645Abstract: The present invention relates to a bioactive molecule, herein referred to as the CD8+ suppressor molecule, that is produced by the CD8+ subset of human T-lymphocytes and suppresses type-1 human immunodeficiency virus (HIV-1) replication through inhibition of viral transcription. The invention relates to isolation of CD8+ cell lines and cell clones that produce that antiviral activity and to the development of assay systems for detection of the antiviral activity. The cell lines, cell clones and assay systems, described herein, may be utilized, e.g., to purify, characterize and clone the CD8+ suppressor molecule. The CD8+ suppressor molecule may have therapeutic applications for treatment of diseases associated with HIV-1 infection.Type: GrantFiled: February 6, 2002Date of Patent: May 2, 2006Assignee: Duke UniversityInventors: Dani P. Bolognesi, Michael L Greenberg, Simon F Lacey, Georgia D Tomaras, Kent J. Weinhold
-
Patent number: 7026154Abstract: The present invention relates to a method of inactivating enveloped viruses in a viral preparation predominantly containing non-enveloped viruses by the action of a solvent at a temperature of between ?5° C. and +50° C. and at a pH of between about 5 and 9. Its subject is also a method of preparing a viral preparation comprising such a method of inactivation. The invention also relates to a viral preparation obtained according to the method of the invention. Finally, it relates to a host cell and a composition comprising such a viral preparation as well as their uses for therapeutic or prophylactic purposes.Type: GrantFiled: December 21, 1999Date of Patent: April 11, 2006Assignee: Transgene S.A.Inventors: David Gaillac, Michel Koehl
-
Patent number: 7001736Abstract: The present invention provides a method for the determining the appropriate therapy and/or prognosis for a patient diagnosed with a non-Alzheimer's disease (AD) neurological disease based upon the patient's apoE allele load. The invention also provides a method for the identification of human subjects with a non-AD neurological disease that are likely to respond in clinical trials that test pharmaceuticals useful in the treatment of neurological diseases.Type: GrantFiled: February 8, 2000Date of Patent: February 21, 2006Inventor: Judes Poirier
-
Patent number: 6984721Abstract: Immunological reagents obtained from multimeric forms of the HIV-2 and SIV envelope glycoproteins and their use in the detection of HIV-2, particularly, the HIV-2 proteins gp300, p200, p90, and p80, and gp300 of SIV.Type: GrantFiled: December 19, 2000Date of Patent: January 10, 2006Assignee: Institut PasteurInventors: Luc Montagnier, Anne G. Laurent-Crawford, Bernard Krust, Ara G. Hovanessian, Marie-Anne Rey-Cuillé